LifeStance Health Group (NASDAQ:LFST) Director Darren Black Sells 8,407,643 Shares of Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Darren Black sold 8,407,643 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $5.07, for a total transaction of $42,626,750.01. Following the transaction, the director directly owned 33,524,715 shares of the company’s stock, valued at $169,970,305.05. This represents a 20.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $5.35 on Thursday. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.19. The business’s 50 day moving average is $4.67 and its two-hundred day moving average is $6.04. LifeStance Health Group, Inc. has a 12-month low of $3.74 and a 12-month high of $8.61. The stock has a market capitalization of $2.08 billion, a price-to-earnings ratio of -107.00 and a beta of 1.13.

LifeStance Health Group (NASDAQ:LFST) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.01) EPS for the quarter, beating the consensus estimate of ($0.03) by $0.02. LifeStance Health Group had a negative return on equity of 1.11% and a negative net margin of 1.23%.The business had revenue of $345.31 million during the quarter, compared to analysts’ expectations of $345.05 million. During the same period last year, the firm earned ($0.06) EPS. The company’s quarterly revenue was up 10.6% compared to the same quarter last year. LifeStance Health Group has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Research analysts expect that LifeStance Health Group, Inc. will post -0.18 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of LifeStance Health Group from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. BTIG Research began coverage on shares of LifeStance Health Group in a research report on Friday, July 25th. They set a “buy” rating and a $8.00 target price on the stock. Finally, UBS Group increased their target price on shares of LifeStance Health Group from $8.50 to $9.00 and gave the company a “buy” rating in a report on Friday, August 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Hedge Funds Weigh In On LifeStance Health Group

Hedge funds have recently added to or reduced their stakes in the business. DekaBank Deutsche Girozentrale purchased a new stake in shares of LifeStance Health Group in the first quarter valued at about $31,000. Park Edge Advisors LLC purchased a new position in LifeStance Health Group during the second quarter worth $52,000. Bayesian Capital Management LP acquired a new position in shares of LifeStance Health Group in the second quarter worth $52,000. Xponance Inc. acquired a new position in shares of LifeStance Health Group in the first quarter worth $69,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in shares of LifeStance Health Group in the second quarter valued at $70,000. 85.50% of the stock is currently owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.